A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Commentary|Podcasts|August 12, 2025
A New Joint Scientific Statement and What to Watch for at the European Society of Cardiology Congress 2025
Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.
Advertisement
This week, host Craig Beavers tackles the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 through September 1, 2025. Key data to keep an eye on will include the following:
- The VICTORION-Difference study of inclisiran in hyperlipidemia
- The Essence study of olezarsen in hypertriglyceridemia
- Multiple studies on early discontinuation of aspirin after percutaneous coronary intervention in high-risk acute coronary syndromes
- The DAPT-SHOCK-AMI trial of cangrelor in patients with cardiogenic shock related to acute myocardial infarction
- The ALONE-AF trial about stopping anticoagulation after successful atrial fibrillation ablation
- The ODYSSEY-HCM and MAPLE-HCM studies on mavacamten and aficamten in hypertrophic cardiomyopathy
Stay tuned for upcoming episodes for deeper dives into these data and other key takeaways from ESC.
Advertisement
Related to this article
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5